Preclinical ARDS Model | LPS-Induced Acute Lung Injury

Preclinical ARDS and Acute Lung Injury Models

Acute respiratory distress syndrome (ARDS) is a severe inflammatory lung condition associated with pulmonary dysfunction, hypoxemia, increased alveolar-capillary permeability, inflammatory cell recruitment, and acute tissue injury.

IPS Therapeutique offers LPS-induced acute lung injury models in mice to support the preclinical evaluation of therapies targeting ARDS-relevant inflammatory and pulmonary injury pathways.

These models are designed to assess treatment effects on lung inflammation, BALF cellularity, cytokine release, respiratory function, lung injury, and histological evidence of inflammatory tissue damage.

Because rodent LPS models reproduce selected features of human ARDS rather than the full clinical syndrome, IPS Therapeutique emphasizes fit-for-purpose study design, appropriate endpoint selection, and careful interpretation of functional, inflammatory, and histological data.

LPS-Induced Acute Lung Injury Methodology

IPS Therapeutique designs ARDS-relevant acute lung injury studies using LPS-induced pulmonary inflammation in mice.

Available species

Mouse, rats

Disease induction and progression

Single LPS administration
Intratracheal or intranasal delivery, depending on study design
Acute inflammatory lung injury
BALF inflammatory cell recruitment
Cytokine and chemokine release
Histological evidence of lung inflammation and tissue injury

Typical study design

In-life disease phase: approximately 3 days
Total study duration: approximately 3 weeks
Preventive or therapeutic dosing designs
Flexible treatment route according to test article properties
Terminal BALF collection, lung tissue collection, and histology
Functional respiratory assessment, when required

Model design considerations

LPS models reproduce acute inflammatory lung injury with ARDS-relevant features
The model is useful for evaluating anti-inflammatory and lung-protective effects
Timing of treatment and sample collection is critical
BALF, cytokine, functional, and histological endpoints should be interpreted together
Study design should be adapted to the therapeutic mechanism of action

ARDS and Acute Lung Injury Readouts and Applications

IPS Therapeutique combines functional, inflammatory, biochemical, and histological endpoints to evaluate therapeutic activity in LPS-induced acute lung injury models.

Clinical and functional readouts

Body weight change
Clinical observations
Lung index
Whole-body plethysmography
Respiratory pattern analysis
Oxygen saturation, when applicable

BALF and inflammatory readouts

BALF total cell count
BALF differential cell count
Neutrophil recruitment
Macrophage recruitment
Pro-inflammatory cytokines
Chemokines and inflammatory mediators

Histological readouts

H&E lung histology
Inflammatory cell infiltration
Alveolar and airway injury
Tissue edema and inflammatory thickening
Semi-quantitative lung injury scoring
Morphometric analysis, when applicable

Drug development applications

ARDS-relevant efficacy testing
Acute lung injury studies
Anti-inflammatory drug evaluation
Lung-protective therapy assessment
Inhaled, intranasal, systemic, biologic, or cell-based therapeutic programs
Dose-response and treatment-timing studies
Mechanism-of-action support

Interpretation matters

LPS-induced acute lung injury is a useful preclinical tool, but it should not be overinterpreted as a complete model of human ARDS. Its value comes from well-controlled execution, mechanism-driven endpoint selection, and integrated interpretation of inflammatory, functional, and histological outcomes.